Neurogene (NGNE) Other Operating Expenses (2013 - 2019)

Neurogene's (NGNE) quarterly Other Operating Expenses came in at $47.7 million in Q3 2019, up 3534618.52% on a QoQ basis from -$1350.0 in Q3 2014.

Neurogene (NGNE) Other Operating Expenses (2013 - 2019) Analysis & Trends

Neurogene (NGNE) has 3 years of Other Operating Expenses data on file, last reported at $47.7 million in Q3 2019.

Quarterly Other Operating Expenses changed N/A year-over-year to $47.7 million in Q3 2019, while the trailing twelve-month figure through Jun 2020 was $47.7 million (changed N/A YoY) and the FY2019 annual result came in at $47.7 million, changed N/A from the prior year.
Other Operating Expenses advanced to $47.7 million in Q3 2019, from -$1350.0 in the prior quarter.
In the past five years, Other Operating Expenses ranged from a high of $47.7 million in Q3 2019 to a low of $47.7 million in Q3 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Neurogene	815.03 Mn	815.03 Mn	-

Download Data